TRPM2 Expression is Elevated in EGFRm NSCLC Cell Lines with Acquired Resistance to Osimertinib and in Most EGFRm NSCLC Tissues Relapsed from EGFR‐TKI Treatment. Here, TRPM2 is linked to non-small cell lung carcinoma.